RIO RANCHO, N.M.– NTx, a life sciences company developing next-generation platforms for RNA and protein manufacturing, announced today the appointment of Dr. Jeff Coller, Bloomberg Distinguished Professor of RNA Biology and Therapeutics at Johns Hopkins University, to its Scientific Advisory Board (SAB).
“Jeff is a world-renowned scientist whose pioneering discoveries have fundamentally shaped the field of RNA biology,” said Dr. Jamie Coffin, President and Chief Executive Officer of NTx. “His expertise will be instrumental in guiding our technology as we continue to build platforms that can accelerate the future of RNA-based medicines.”
Dr. Coller is widely recognized as a leading authority in RNA and mRNA biology. His groundbreaking research on mRNA stability and translation has reshaped the understanding of gene expression and contributed to the development of mRNA vaccines, including SPIKEVAX.
He previously directed the RNA Center at Case Western Reserve University and co-founded Tevard Biosciences, a company recognized with Pfizer’s Golden Ticket award. Dr. Coller is also a founding member of the Alliance for mRNA Medicines and serves on multiple scientific advisory boards across the biotechnology sector.
“NTx is pioneering new ways to harness RNA biology for therapeutic innovation,” said Dr. Coller. “I am thrilled to contribute to the Scientific Advisory Board and collaborate with this outstanding team as we explore how advances in RNA and mRNA biology can be translated into breakthrough therapies that improve human health.”
